Nan Fung Life Sciences

Nan Fung Life Sciences (NF-LS) operates as a global investment platform dedicated to the life sciences sector, backed by a significant, long-term capital commitment from the Nan Fung Group, a prominent Hong Kong-based conglomerate. With a strategic presence across key global hubs, including offices in Hong Kong, New York, and San Francisco, NF-LS demonstrates a truly international reach. The firm's investment mandate is broad, encompassing the full spectrum of life sciences, from groundbreaking therapeutics and innovative medical devices to advanced diagnostics and transformative digital health solutions.

The firm employs a flexible investment strategy, deploying capital across various stages of company development. This includes early-stage private companies poised for growth, as well as more mature private and even public entities. A significant milestone for the firm was the closing of its inaugural fund, NF-LS Fund I, L.P., in March 2021, which secured total commitments of approximately $450 million. This substantial capital base underscores NF-LS's capacity to make meaningful investments and support its portfolio companies through multiple funding rounds.

NF-LS typically engages in first-check investments that range from several million dollars for promising early-stage opportunities, often in the Series A or B rounds, up to tens of millions for more established, later-stage companies. While specific check sizes are not publicly disclosed, their participation in large funding rounds for companies like ReCode Therapeutics and Septerna, which have raised over $100 million in single rounds, indicates their ability to write substantial checks and act as significant partners. The firm seeks to back companies with robust scientific foundations, disruptive technologies, and clear pathways to market leadership, leveraging its global network and deep industry expertise to foster innovation and growth within its portfolio.